Cullinan Pearl

In conjunction with Taiho Pharmaceuticals, Cullinan Pearl is developing CLN-081, an orally available tyrosine kinase inhibitor designed to target EGFR (Epidermal Growth Factor Receptor) exon 20 mutations. Cullinan was intrigued with the selectivity index of this molecule across a range of biochemical and in vitro assays; namely the molecule’s ability to inhibit EGFR variants with exon 20 mutations while sparing wild-type EGFR.

Cullinan Pearl Poster

Poster – Multicenter Phase 1/2a trial of CLN-081 (TAS6417) in NSCLC Patients with EGFR Exon 20 Insertion Mutations – presented at WCLC 2019

Cullinan Pearl Poster

Poster – Preliminary Safety and Activity of CLN-081 in NSCLC with EGFR Exon 20 Insertion Mutations (Ins20) – presented at ESMO 2020